Mass spec technology by Shimadzu unveils novel approach for immunotherapy success
Source: Bio Spectrum Asia Edition, October 2021
Japan’s Shimadzu Corporation collaborated with Drs William Redmond and Yoshinobu Koguchi of the Providence Cancer Institute (Portland, Oregon, US) to find a biomarker for the clinical outcome of cancer patients treated with anti-CTLA-4 antibody ipilimumab (YERVOY®).
